Clinical characteristics according to Aur-A expression in leukemia blasts
| . | Total (N = 98) . | Aur-A expression . | |
|---|---|---|---|
| Low (N = 33) . | High (N = 65) . | ||
| Median age, y (range) | 40.1 (12-73) | 41.4 (12-73) | 39.4 (12-72) |
| Sex, male/female | 59/39 | 22/11 | 37/28 |
| WBC, median no. ×103/μL (range) | 43.45 (0.25-212.4) | 29.38 (0.44-196.2) | 50.59 (0.25-212.4) |
| FAB classification | |||
| M0 | 3 | 0 | 3 |
| M1 | 6 | 1 | 5 |
| M2 | 25 | 10 | 15 |
| M3 | 18 | 8 | 10 |
| M4 | 8 | 2 | 6 |
| M5 | 35 | 10 | 25 |
| M6 | 3 | 2 | 1 |
| Flt3 genotype | |||
| WT | 67 | 20 | 47 |
| ITD | 27 | 11 | 16 |
| TKD mutations | 7 | 4 | 3 |
| ITD/TKD mutations* | 3 | 2 | 1 |
| Flt3 expression | |||
| High | 63 | 27 | 36 |
| Low | 35 | 6 | 29 |
| Aur-B expression | |||
| High | 40 | 7 | 33 |
| Low | 58 | 26 | 32 |
| . | Total (N = 98) . | Aur-A expression . | |
|---|---|---|---|
| Low (N = 33) . | High (N = 65) . | ||
| Median age, y (range) | 40.1 (12-73) | 41.4 (12-73) | 39.4 (12-72) |
| Sex, male/female | 59/39 | 22/11 | 37/28 |
| WBC, median no. ×103/μL (range) | 43.45 (0.25-212.4) | 29.38 (0.44-196.2) | 50.59 (0.25-212.4) |
| FAB classification | |||
| M0 | 3 | 0 | 3 |
| M1 | 6 | 1 | 5 |
| M2 | 25 | 10 | 15 |
| M3 | 18 | 8 | 10 |
| M4 | 8 | 2 | 6 |
| M5 | 35 | 10 | 25 |
| M6 | 3 | 2 | 1 |
| Flt3 genotype | |||
| WT | 67 | 20 | 47 |
| ITD | 27 | 11 | 16 |
| TKD mutations | 7 | 4 | 3 |
| ITD/TKD mutations* | 3 | 2 | 1 |
| Flt3 expression | |||
| High | 63 | 27 | 36 |
| Low | 35 | 6 | 29 |
| Aur-B expression | |||
| High | 40 | 7 | 33 |
| Low | 58 | 26 | 32 |
FAB indicates French-American-British; WT, wild-type Flt3; ITD, Flt3 internal tandem duplication; and TKD, the activation loop of the tyrosine kinase domain.
ITD/TKD mutations indicate that AML patients had both ITD and TKD mutations and were included in both ITD and TKD mutations groups.